Mesoblast (ASX:MSB) said that its allogeneic cellular products will not be impacted by the US government's recently implemented tariffs on imported goods, according to a Friday filing with the Australian bourse.
The company clarified that these products are derived from US donors and are classified as US-origin, making them exempt from the tariffs.